Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the company announced Wednesday, a move that comes as President Trump is ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

The image of Israeli hostage Eli Sharabi being released from Gaza a little over two weeks ago, looking gaunt and weak, shocked and angered Israel and leaders around the world. His brother Sharon ...

WASHINGTON — Eli Lilly plans to spend $27 billion to build four new drug manufacturing sites in the United States, the company announced Wednesday, at a time when the Trump administration is ...

The UAN activation and linking of bank accounts with Aadhaar is necessary to avail of benefits under the EPFO’s ELI Scheme. “… the competent authority has granted an extension of the ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...

Eli Lilly is buying a new drug and lowering prices on an existing one. GLP-1 weight loss drug Zepbound is getting cheaper. This will make Lilly's product relatively more attractive, and help to ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...